GlassScriptPhysician profile
Angela M Vickroy
NPI 1194060681
$14,890.92
in general payments reported to CMS, 2019-2025
13 companies · $3,941 in 2025
The $3,941 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $323 · 2022: $46.96 · 2023: $5,220 · 2024: $5,360 · 2025: $3,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $975 · Travel and Lodging: $329 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,117.00 |
| Food and Beverage | $975.08 |
| Travel and Lodging | $329.03 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $6,546.87 | 2023-2025 | Tecvayli, Darzalex, Carvykti |
| Janssen Scientific Affairs, LLC | $2,809.26 | 2024-2025 | Talvey, Carvykti, Darzalex |
| Legend Biotech USA INC. | $2,517.77 | 2023-2025 | Carvykti |
| E.R. Squibb & Sons, L.L.C. | $1,967.00 | 2024-2025 | |
| Abbvie INC. | $272.23 | 2023-2024 | |
| Karyopharm Therapeutics INC. | $196.29 | 2021-2023 | Xpovio |
| Pfizer INC. | $188.73 | 2025 | |
| Adaptive Biotechnologies Corporation | $118.92 | 2021 | |
| Tg Therapeutics, INC. | $110.64 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Celgene Corporation | $29.75 | 2022 | |
| Incyte Corporation | $17.21 | 2022 | |
| Merck Sharp & Dohme LLC | $16.26 | 2024 | Lynparza, Keytruda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Vickroy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.